Profil
John Yates served as President & Chief Executive Officer at Takeda Global Research & Development Center, Inc. from 2004 to 2007.
Prior to that, he was Vice President-Medical & Scientific Affairs at Merck & Co., Inc. from 1990 to 2003.
He also served as Chief Medical Officer at Array BioPharma, Inc. from 2007 to 2008.
Currently, he is the Chief Medical Officer at Radius Health, Inc. Dr. Yates holds a doctorate degree from The University of Sheffield.
Anciens postes connus de John Yates
| Sociétés | Poste | Fin |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 15/09/2008 |
| Takeda Global Research & Development Center, Inc. | President | 01/01/2007 |
| MERCK & CO., INC. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
| RADIUS HEALTH, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de John Yates
| The University of Sheffield | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
| Takeda Global Research & Development Center, Inc. | |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
